AstraZeneca PLC (AZN.L)
3,334.00GBp
12:08pm EDT
-1.00p (-0.03%)
3,335.00p
3,369.50p
3,379.50p
3,284.00p
2,247,700
2,054,692
3,544.50p
2,786.00p
About
Overall
| Beta: | 0.41 |
| Market Cap (Mil.): | £41,844.39 |
| Shares Outstanding (Mil.): | 1,252.22 |
| Dividend: | 122.26 |
| Yield (%): | 5.40 |
Financials
| AZN.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 11.25 | 37.93 | 37.76 |
| EPS (TTM): | 2.97 | -- | -- |
| ROI: | 15.60 | 19.48 | 18.76 |
| ROE: | 25.88 | 20.17 | 19.59 |
WRAPUP 1-Drugmakers fear short-term "turmoil" as China probes widen
* AstraZeneca CEO sees short-term disruption, price pressure
AstraZeneca unit looking at biosimilars, no comment on Celltrion
LONDON, Aug 1 - AstraZeneca is looking at ways to leverage its capacity to make biotech drugs within its MedImmune unit, including a possible move into so-called biosimilars, its chief executive said on Thursday.
AstraZeneca warns of higher costs as drug sales slide
LONDON - British drugmaker AstraZeneca warned on Thursday of higher costs in 2013 as it invests through a slump in sales caused by a wave of patent expiries on key medicines.
UPDATE 2-AstraZeneca warns of higher costs as drug sales slide
LONDON, Aug 1 - British drugmaker AstraZeneca warned on Thursday of higher costs in 2013 as it invests through a slump in sales caused by a wave of patent expiries on key medicines.
AstraZeneca drug sales fall on patent expiries in second quarter
LONDON, Aug 1 - AstraZeneca sales fell by a slightly more -than-expected 6 percent in the second quarter, hurt by loss of patent protection on key drugs, while earnings tumbled nearly a quarter due to a higher tax rate.
UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal
LONDON, July 31 - AstraZeneca took another step to bolster its new drug pipeline on Wednesday by striking a deal with U.S. biotech firm FibroGen potentially worth more than $815 million for rights to an experimental anaemia drug.
BRIEF-Source Bioscience provides update on funding for Vindon Healthcare buy
July 24 - Source Bioscience plc : * Update re funding for possible offer * Conditionally raised GBP 9.5 million firm with new and existing institutional
UPDATE 3-U.S. citizen detained as China pharma probe spreads
* 39 hospital staff to be punished for taking bribes-Xinhua
Array asthma drug meets main goal in mid-stage study
- Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma.
Two more AstraZeneca employees questioned in China
LONDON - Chinese police have questioned two more AstraZeneca employees in Shanghai, after a sales representative was taken away for questioning earlier, the British drugmaker said on Tuesday.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

